Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Next Previous
Trial Profile

A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Hyponatraemia; Inappropriate antidiuretic hormone secretion
  • Focus Pharmacodynamics
  • Sponsors Otsuka Pharmaceutical Development & Commercialization

Most Recent Events

  • 12 Aug 2017 Results of this and other study comparing low dose tolvaptan in patients with hyponatremia with healthy adults, published in the European Journal of Clinical Pharmacology.
  • 22 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 07 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 May 2015 according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top